Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Non-Current Assets (2016 - 2025)

Assembly Biosciences (ASMB) has 11 years of Non-Current Assets data on record, last reported at $3.2 million in Q3 2025.

  • For Q3 2025, Non-Current Assets rose 55.44% year-over-year to $3.2 million; the TTM value through Sep 2025 reached $13.7 million, up 33.96%, while the annual FY2024 figure was $3.7 million, 20.72% up from the prior year.
  • Non-Current Assets reached $3.2 million in Q3 2025 per ASMB's latest filing, down from $3.3 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $60.8 million in Q3 2021 and bottomed at $2.0 million in Q3 2023.
  • Average Non-Current Assets over 5 years is $16.1 million, with a median of $3.5 million recorded in 2025.
  • Peak YoY movement for Non-Current Assets: crashed 89.45% in 2023, then surged 55.44% in 2025.
  • A 5-year view of Non-Current Assets shows it stood at $36.9 million in 2021, then crashed by 86.9% to $4.8 million in 2022, then plummeted by 37.1% to $3.0 million in 2023, then increased by 20.72% to $3.7 million in 2024, then fell by 13.1% to $3.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Assets were $3.2 million in Q3 2025, $3.3 million in Q2 2025, and $3.5 million in Q1 2025.